Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mega Genomics Limited ( (HK:6667) ) has issued an announcement.
Mega Genomics reported unaudited interim results for the six months ended 30 June 2025 showing revenue of RMB81.3 million, down 24.2% year-on-year, and net profit of RMB27.3 million, a decline of 26.3%. The company attributed the weaker top- and bottom-line performance mainly to a strategic adjustment in its sales approach, which temporarily reduced revenue while fixed costs such as labor, rent and depreciation limited flexibility on expenses. Consumer genetic testing and ancillary services, its core business, saw revenue fall 27.3% to RMB75.9 million, while cancer screening services and ancillary services nearly doubled, jumping 85.7% to RMB5.3 million. Despite the revenue contraction, gross profit margin improved significantly to 74.0% from 64.9%, indicating better pricing or cost efficiency, though net profit margin edged down slightly to 33.5%. The results highlight a near-term financial impact from the sales strategy shift even as the company maintains wide geographic coverage and seeks growth in higher-potential cancer screening services, factors that will be closely watched by investors and healthcare partners.
More about Mega Genomics Limited
Mega Genomics Limited is a leading genetic testing platform company in China, specializing in consumer genetic testing services and ancillary services, as well as cancer screening tests and related offerings. The group has performed more than 24 million genetic tests and, according to industry consultancy Frost & Sullivan, ranks as the country’s largest consumer genetic testing platform by cumulative tests and the largest cancer screening genetic testing platform by test volume in recent years, serving healthcare institutions in over 340 cities and partnering with e-commerce and online healthcare platforms to extend its market reach.
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.61B
Learn more about 6667 stock on TipRanks’ Stock Analysis page.